David Huffman
Psychiatric/Mental Health · Columbus, OHNPI 1063860526
Payments from drug & device makers
Across 827 payments — averaging $60.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$41K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$1K
- Lundbeck LLC$974
- Neurocrine Biosciences, Inc.$960
- Supernus Pharmaceuticals, Inc.$719
- plus $4K from 16 others
What the payments were for
- Speaking & faculty fees$36,32572%
- Travel & lodging$1,1622%
- Food & beverage$12,75325%
- Education$1210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 322 | $40,962 |
| Otsuka America Pharmaceutical, Inc. | 76 | $1,285 |
| Johnson & Johnson(2 entities) | 60 | $1,099 |
| Lundbeck LLC | 47 | $974 |
| Neurocrine Biosciences, Inc. | 48 | $960 |
| Supernus Pharmaceuticals, Inc. | 37 | $719 |
| Axsome Therapeutics, Inc. | 32 | $700 |
| Vanda Pharmaceuticals Inc. | 29 | $677 |
| E.r. Squibb & Sons, L.L.C. | 31 | $650 |
| Alkermes, Inc. | 33 | $530 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $418 |
| Teva Pharmaceuticals USA, Inc. | 21 | $353 |
| Sunovion Pharmaceuticals Inc. | 15 | $240 |
| Tris Pharma Inc | 24 | $210 |
| Corium, LLC | 10 | $180 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $146 |
| Indivior Inc. | 5 | $111 |
| Idorsia Pharmaceuticals US Inc | 3 | $43 |
| Ironshore Pharmaceuticals Inc. | 2 | $42 |
| Noven Therapeutics, LLC | 2 | $29 |
| Almatica Pharma LLC | 1 | $19 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,361 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 178 | $239,426 |
| Abilify MaintenaAripiprazole | 47 | $133,851 |
| Austedo XrDeutetrabenazine | 11 | $96,571 |
| Invega SustennaPaliperidone Palmitate | 35 | $91,254 |
| Lurasidone Hcl | 106 | $41,423 |
| Paliperidone ErPaliperidone | 118 | $32,495 |
| RexultiBrexpiprazole | 21 | $31,348 |
| AuvelityDextromethorphan Hbr/Bupropion | 21 | $25,791 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 40 | $21,285 |
| TrintellixVortioxetine Hydrobromide | 35 | $19,265 |
| BelsomraSuvorexant | 39 | $16,926 |
| Aripiprazole | 256 | $12,843 |
| QuviviqDaridorexant Hcl | 24 | $12,842 |
| Chlorpromazine Hcl | 43 | $11,807 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 118 | $7,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $40,962 | $239,426178 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,285 | $165,19968 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $353 | $96,57111 claims |
| Johnson & JohnsonInvega Sustenna | $1,099 | $91,25435 claims |
| Axsome Therapeutics, Inc.Auvelity | $700 | $25,79121 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $146 | $19,26535 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $43 | $12,84224 claims |
| Almatica Pharma LLCSertraline Hcl | $19 | $1,537325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Columbus
- Holly SchweitzerColumbus$78K
- Tarsicio GacheruColumbus$18K
- Alicja MatusiakColumbus$11K
- Summer LawsonColumbus$11K
- Gregory BlankenshipColumbus$10K
- Jennifer WilsonColumbus$10K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.